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Abstract: The ability of a cell to respond to a particular hormone depends on the presence of 
specific receptors for those hormones. Once the hormone has bound to its receptor, and following 
structural and biochemical modifications to the receptor, it separates from cytoplasmic chaperone 
proteins, thereby exposing the nuclear localization sequences that result in the activation of the 
receptor and initiation of the biological actions of the hormone on the target cell. In addition, recent 
work has demonstrated new pathways of steroid signaling through orphan and cell surface receptors 
that contribute to more rapid, “non-nuclear” or non-transcriptional effects of steroid hormones, often 
involving G-protein-mediated pathways. This review will summarize some of these studies for 
estrogens, androgens and progestins. 
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1. Introduction 
There are two types of binding proteins in the superfamily of intracellular receptors: one 
consists of the unbound receptor of the thyroid hormones, which is fixed on DNA and represses 
transcription, only to be activated when the thyroid hormone enters the cell and binds, and the second 
type of receptor protein, that for steroid hormones, which is unable to bind DNA in the absence of its 
ligand. Only the formation of the hormone-receptor complex produces conformational changes that 
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allow transfer into the nucleus and binding to the specific DNA sequences that regulate gene 
transcription. Once in the nucleus, these steroid-receptor complexes regulate transcription by binding, 
usually as dimers, to the response elements normally localized in the regions of the responsive target 
genes. 
The receptors for androgens and estrogens are members of the superfamily of nuclear receptors 
that also include those for progesterone, glucocorticoids, mineralocorticoids, vitamin D, thyroid 
hormones and retinoic acid; all of these hormones can freely diffuse across the plasma membrane 
and bind with their receptors that then interact with specific binding sites on DNA, thus acting as 
“transcription factors regulated by hormones”. Furthermore, emerging evidence has revealed new 
pathways of steroid signaling through receptor subfractions localized at the cell membrane that have 
been implicated as responsible for the non-nuclear effects of steroid hormones [1,2]. These 
non-conventional signaling mechanisms are often wrongly named “non-genomic” or “non-nuclear”; 
however they may be more properly labeled “non-transcriptional” so as to emphasize that DNA 
binding of the receptors and RNA synthesis are not required. 
2. Cell membrane sex steroid receptors 
The sex steroid receptors (SSRs) are transcription factors mainly localized in the cytoplasm but 
also to the cell membrane, that regulate the expression of target genes by binding to specific 
sequences present at the level of DNA called “sex steroid response elements” (SSRE). These are 
nucleotide sequences specifically recognized by the hormone-receptor complex [3]. This leads to 
nuclear translocation of ligand and homo or heterodimeric receptors to the SSRE on the promoter of 
target genes, thereby regulating gene expression [4]. In particular, SSR activation is mediated by two 
transcriptional activating domains, respectively called AF-1 and AF-2. AF-1 is localized in the 
N-terminal region and is characterized by a ligand-independent transcriptional activity, while AF-2 is 
localized within the ligand-binding domain (LBD) and shows ligand-dependent transcriptional 
activity [5]. This activated complex coordinates the formation of protein complexes composed of 
several coactivators or corepressors localized on chromatin of their target genes. 
The dimerization of the receptors occurs in response to ligand binding; this causes a 
conformational change that exposes a surface of the receptor with which the transcriptional 
regulators can interact. The dimer binds SSRE elements that are found in the promoters of genes that 
respond to sex steroids [6]. For example, some of the coactivator family members of the steroid 
receptors (SRC) p160 (SRC-1, SRC-2 and SRC-3) bind SSRE through one of three LXXLL motifs, 
forming amphipathic alpha-helices [7]. The coactivators that are involved belong to the p160 SRC 
family, which consists of SRC-1 (NCOA-1), SRC-2 (GRIP1/TIF2/NCOA-2), and SRC-3 
(AIB1/TRAM-1/ACTR/RAC3/PCIP), proteins more specific for estrogen and progesterone receptors [8], 
whilst ARA70 and TBLR1 are specific for androgen receptors. The hormone-receptor pairs form a 
homodimeric complex on specific regulatory elements of the DNA that activate or repress 
steroid-regulated gene transcription by RNA polymerase, leading to altered levels of specific mRNA. 
The translation of the RNA messages on cytoplasmic ribosomes influences the appropriate proteins 
that alter cell function, growth or differentiation. In the absence of hormone, sex steroid receptors 
(which includes androgen, progesterone and estrogen receptors) exist as inactive oligomeric complexes 
that are sequestered in the cytoplasm by the heat-shock protein (Hsp) 90, which behaves as a molecular 
chaperone, as well as heat shock proteins 70, cyclophilin 40, FKBP51, and FKBP52 [9,10]. Another 
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chaperone, called p23, stabilizes the aporeceptor complex by blocking Hsp90 in the ATP-bound 
substrate conformation. Co-chaperones utilizing tetratricopeptide repeat motifs are necessary for 
binding of Hsp90. Furthermore, other chaperones called Hsp40 and Hsp70 and an organizing protein 
called heat-shock organizing protein (Hop) are important in the assembly of the steroid 
receptor-Hsp90 complex [11]. 
The steroid receptor-Hsp90 complex seems to be necessary for the receptor to stabilize in a 
conformation for binding to the ligand with high affinity and also to maintain its solubility in the cell. 
In addition, although the receptor is held in this complex, it is inactive as a transcription factor, 
explaining why the Hsp90 complex works as a repressor of transcriptional activity: it prevents 
nuclear localization, dimerization, DNA binding and interaction of the complex with transcriptional 
coactivators [12]. Once in the nucleus, SSR binds to the SSREs on promoter/enhancer regions, 
recruits coregulators, and forms the transcriptional machinery for SSR-regulated gene expression. 
This SSR-signaling pathway is known as the “genomic pathway” and relies on SSR nuclear 
translocation and SSR-DNA binding for cell proliferation. This pathway is characterized by 
increased expression of specific SSR-regulated genes. There are interacting cofactors that improve 
(i.e.: coactivators) or reduce (corepressors) steroid receptor activation without having any significant 
effect on the level of basal transcription.  
3. Non-genomic signaling mechanisms of sex steroid hormones 
There is a much more rapid and reversible pathway that has been shown to be involved in the 
regulation of cell proliferation particularly in prostate cancer [13,14]. This signaling pathway is 
known as the “non-genomic pathway”, and it requires neither SSRs nuclear translocation nor 
SSR-DNA binding.  
Activated SSRs in the cytoplasm, but especially in the plasma membrane, can stimulate second 
messenger cascades, interacting with several signaling molecules like phosphatidyl-inositol 3-kinase 
(PI3K)/Akt, the non-receptor tyrosine kinase c-Src (Src), Ras-Raf-1, protein kinase A (PKA) and 
protein kinase C (PKC), which in turn converge on mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) activation, leading to cell proliferation [15]. 
The SSRs can be localized in the plasma membrane or be in specialized micro domains of the lipid 
bilayer that are enriched with sphingolipids, caveolins, Src family kinases, and G proteins, called 
“lipid rafts” [16]. In this regard there is a great deal of evidence for the interaction between AR 
(androgen receptor), ER (estrogen receptor), PR (progesterone receptor) and the tyrosine kinase 
domain of Src, leading to its activation. The latter is well known to be localized in the inner side of 
the plasma membrane through post-traslational modifications like myristylation or palmitoylation in 
the N-terminus that determine a physical interaction with caveolin-1 [17]. Src homology 2 (SH2) and 
Src homology 3 (SH3) cause an autoinhibition of Src that is relieved when SSR bind SH3 activating 
an adaptor protein (Shc) that regulates MAPK/ERK-1/2 signaling pathway [18]. Most sex steroids 
bind sex hormone-binding globulin (SHBG) when circulating in the bloodstream, a protein produced 
in liver under the influence of these same steroids. The affinity by which hormones bind SHBG is 
different; particularly, androgens have high affinity for SHBG compared to estrogens. Nowadays it is 
well established that there is a SHBG receptor (SHBGR), a G-protein coupled receptor, that activates 
a signaling cascade mediates by cAMP. This leads to the activation of PKA pathways that induce a 
phosphorylation status change of steroid receptors, and their coregulators that modulate SR 
transcriptional activity. To induce the cAMP pathway SHBG must first bind to the SHBGR, which is 
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followed by steroid binding. If steroid binding comes first, interaction with the SHBG receptor 
cannot happen, though both of these mechanisms may potentially influence the transcriptional 
activation of the nuclear SR. In addition, the SHBGR may directly bind steroids or indirectly 
influence the activity of a membrane steroid-binding protein. One of the effects mediated by this 
putative receptor is to increase intracellular calcium levels. The elevation of intracellular calcium 
activates signal transduction cascades including PKA, PKC and MAPK, and can modulate the 
activity of transcription factors [19]. 
4. Sex steroid hormone actions  
4.1. Estrogen receptors 
Despite estrogens belonging to the family of sex steroid hormones they are involved in the 
regulation of many physiological and pathological processes. Estrogen and its receptors mainly exert 
their effect on the reproductive system but also modulate differentiation, metabolism, and cell 
proliferation, as well as pathological processes including breast and endometrial cancer and 
osteoporosis [20].  
Among the target tissues of estrogens are breast, endometrium, bone, brain, liver and heart. Like 
other steroid hormones they are synthesized from cholesterol, which is also the starting molecule for 
the androgenic compounds androstenedione and testosterone. Estrogens are first converted to 
progestins, androgens, and finally, through a series of enzymatic reactions, into estrogens. They are 
mainly synthesized in the ovaries in premenopausal women; in older women and in men the main 
site for the synthesis of estrogen is the peripheral tissue, especially adipose tissue [21]. In addition to 
this, the aromatization of testosterone to estradiol makes available a source of estrogen that can bind 
estrogen nuclear receptors and promote estrogenic actions on the hypothalamus, pituitary, bone, 
lipids and cardiovascular system. 
The most important forms of estrogens include 17-estradiol, estrone and estriol. The first is the 
most potent and it is produced and secreted from ovaries and moves throughout the body; the others 
are produced in the liver and adrenal glands, and have less effect than 17β-estradiol [22]. Recently a 
new isoform of estrogen named estrone sulfate has been identified. It is the most abundant form of 
circulating estrogen during the postmenopausal period, as well as in non-pregnant women and men. 
This isoform can be converted to estrone by sulfatase enzyme activity and then into estradiol. It is 
noteworthy that estradiol is the most potent estrogen in premenopausal women, estrone in 
postmenopausal women, and estriol in pregnant women [23,24]. 
Estrogens, in addition to acting on the reproductive system, perform their function in the skin 
and mucous membranes [25]; at the sebaceous-follicle level, they reduce the secretion of sebum and 
facilitate hair growth [26]; at the level of the bone they play a positive role in metabolism [27], while 
in adipose tissue estrogens work on the deposition of fat, characteristic for women; they also promote 
lipogenesis and insulin secretion [28]. 
Estrogen activities are exerted through intracellular receptors that regulate gene expression after 
their movement into the nucleus. Indeed, these effects can be rapid or take several days, so a 
difference needs to be established between transcription-independent (nongenomic) and 
transcription-dependent (genomic) actions [29]. Some effects of estrogen cannot be justified by 
purely genomic mechanisms due to the rapidity of their effects. Estrogen receptors are found in cell 
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membrane invaginations called caveolae. Human studies on osteoblasts, endothelial cells, neurons, 
and breast cancer cells show a relationship between estrogen interaction with its receptor on the cell 
membrane and the mitogen-activated protein kinase cascade [30]. 
The classical pathway of gene activation by estrogen takes from 30 minutes to several hours; 
non-genomic pathways, unlike the classical, are characterized by a more rapid response time, from a 
few seconds to about ten minutes. The latter also mediates responses such as immediate vasodilation of 
the coronary arteries and the effect of estrogen on the rapid insulinotropic cells of the pancreas [31]. 
Estrogen action in different target tissues is carried out through binding to the nuclear estrogen 
receptors α and β; the first was previously cloned from rat uterus in 1987 [32] while the second was 
cloned from rat prostate and is highly expressed in the secretory epithelial cells of the prostate and 
also in the granulosa cells of the ovary [33]. The two receptors are located on different chromosomes: 
in humans (which is different from other organisms) chromosome 6 contains the alpha isoform and 
chromosome 14 the beta isoform. These receptors are present in the target cells and are 
ligand-dependent transcription factors; that is they are inactive until they are bound by their ligand. 
Some evidence suggests the presence of ERs also at the level of mitochondria and endosomes of 
some cells in breast cancer and in endothelial cells. In this capacity, ERs could inhibit the production 
of mitochondrial reactive oxygen species (ROS) essential to induce cell death in cancer cells. This 
would lead to the survival of tumor cells [34]. 
With regards the estrogen receptor (ER), both nuclear and membrane/cytoplasmic pools of ER α 
and ER β have affinity for steroid ligand. Estrogens activate or repress gene transcription by binding 
target nuclear receptors, forming a steroid-receptor complex that binds to DNA response elements in 
the promoter of the estrogen-target genes.  Another mechanism involves the interaction of nuclear 
estradiol (E2)/ER with transcription factors such as activator protein 1 (AP-1) or Sp-1. 
Recent studies have suggested the idea that both ER-α and the nuclear membrane form are 
derived from the same gene and are the same protein in a variety of cells, including breast cancer. 
Membrane ER rapidly activates signaling through G-protein coupled receptors to generate calcium 
flux by stimulating cAMP and cGMP production, and activating PI3K and  extracellular 
signal-regulated kinase (ERK) pathway activation.  Rapid estrogen signaling from the pool of cell 
membrane ER has an effect on gene transcription and non-genomic functions. In all of these ways, 
ER membrane signaling contributes to many actions of this sex steroid in breast cancer cells [35]. 
A dynamic post-translational modification, palmitoylation, facilitates interaction with caveolin-1 
(Cav-1), which carries a limited group of these steroid receptors to plasma membrane caveolae rafts 
(CR). At the membrane level, ER is bound by estrogen, activating rapid signals including G-proteins 
and Src. 
Even if they have a high homology with the ERs, estrogen-related receptors (ERRs) are a family 
of nuclear receptors that are constitutively active transcription factors regulating many homeostatic 
processes [36]. These do not bind estradiol and instead activate transcription in a ligand-independent 
way, hence their classification as orphan nuclear receptors [37]. The ERRs were previously used to 
discover estrogen-receptor beta by comparing the sequence with that of the receptor α [38]. There is 
a strong conservation among ERRs and ERs: 36% in the ligand-binding domain and 68% in the 
DNA-binding domain. The ERRs are able to bind both EREs and ERREs (ERR response elements) 
and modulate the transcription of target genes [39].  
The ligand-independent pathway is a phenomenon that most likely is joined to the classical 
pathway, as it allows the activation of the ER even in the presence of low concentrations of estradiol, 
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amplifies the effects of growth factors, and stimulates mitogenesis within ER-positive tissues [40]. 
Until now there have been identified three different receptors that can regulate these homeostatic 
processes: estrogen-receptor alpha, beta and gamma. ERRα plays a key role in the regulation of 
metabolic processes and is mostly expressed in tissues with high-energy demand, such as heart, 
kidney, skeletal muscle and brown adipose tissue [41]. Evidence shows the potential involvement of 
ERRα in cancer progression and development. Previous studies have shown that suppression of 
ERRα causes tumor cell death through the production of ROS [42]. Moreover, ERRα is involved in 
phosphoenolpyruvate carboxykinase enzyme (PEPCK) regulation, which plays a key role in hepatic 
gluconeogenesis, through action on the transcriptional coactivator PGC-1α. ERRα also increases 
expression of mitochondrial genes such as ATP synthase subunit β and cytochrome c-1, but decreases 
gluconeogenic genes, including PEPCK and glycerol kinase [43].  
The ER family of receptors binds to specific DNA recognition sequences present in conserved 
responsive genes, often found in the neighborhood of the promoters, about 100 kb from the gene 
promoter responsive. The canonical estrogen ERE is the sequence 5'-AGGTCA-3' followed by three 
bases with undetermined sequence, followed by the reverse sequence 5'-TGACCT-3' [44]. The nature 
of the palindromic ERE sequence makes possible the interaction of the two DNA binding domains 
on the receptor. 
It is noteworthy that the ERRα binds particularly well if the canonical sequence is preceded by 
5'-TAA-3' or 5'-TCA-3'. This suggests that the response element to ERRs are formed by 
5'-TA/AGGTCA-3'CA [45]. Regarding the other two receptors ERRβ and ERRγ, it is now known 
that their expression is important for the control of energy balance and food intake. Just as ERRα and 
ERRγ, the expression of ERRβ is abundant in the retina, liver, adipose tissue, and skeletal and 
cardiac muscle [46]. 
ERRγ is mainly expressed in the heart, brain, kidneys, pancreas and liver; it is involved in 
important cellular processes including metabolism of alcohol, the hepatic metabolism of glucose as 
well as the stress response in the endoplasmic reticulum. Studies carried out indicate that ERRs, 
including ERRγ are constitutively active without a natural ligand; there are different ligands that 
stimulate or repress the activity of ERRγ promoting or disrupting its interaction with coactivators [47]. 
Another orphan receptor discovered in 1997 in breast cancer is GPR30. It recently was renamed 
as a G protein-coupled estrogen receptor (GPER) and defined as a functional receptor of estrogen. It 
is mainly localized intracellularly and is not restricted to the cell membrane. This should have an 
important affect on estrogen signaling in many tissues; GPER is coupled with a G protein act to 
activate adenylate cyclase and epidermal growth factor receptor (EGFR) [48]. The activation of 
GPER by binding estrogen causes a mobilization of intracellular calcium and synthesis of 
phosphatidylinositol 3,4,5-triphosphate in the nucleus [49]. Studies in genetic variants of GPER were 
started to better understand its role in the onset of some tumors, such as human seminoma [50]. All 
of these estrogen related receptors are extranuclear mediators for the non-genomic actions of 
steroids. 
4.2. Androgen receptors 
Androgens simultaneously function as sex steroid hormones and anabolic hormones. Their 
anabolic effects on various tissues such as bone, muscle and red blood cells have long been  
known [51]. The side effects are not serious in women even if they have many virilizing effects (e.g. 
300 
 
AIMS Molecular Science  Volume 2, Issue 3, 294-310. 
hirsutism, voice change) but could be dramatic in men by increasing the risk of prostate cancer or 
benign prostatic hyperplasia [52]. 
Testosterone is the principal androgen circulating in the blood and in many tissues it is 
metabolized by 5-alpha-reductase to form 5-alpha-dihydrotestosterone (DHT), which binds to and 
activates the androgen receptor (AR) [53]. Only 0.5‒4% of circulating steroid hormones are free in 
the serum. Approximately 60% is bound to sex hormone-binding globulin (SHBG) with the 
remainder bound to albumin, which has an affinity 1,000 times less than that SHGB. This fraction of 
steroids, being linked with lower affinity and therefore more rapidly dissociable, eventually ends up 
in a pool of free testosterone steroid that is readily usable, so-called bioavailable testosterone, which 
constitutes about 50% of total testosterone [54]. 
The receptor for SHBG has been identified in many tissues including the prostate, testes, breast, 
and liver, but not in lymphocytes and muscle. SHBG, in addition to acting as a regulator of 
concentration, plays a central role in allowing some steroid hormones to act without entering the  
cell [55]. SHBG is a glycoprotein of 373 amino acids, known as a carrier protein, produced by the 
liver and secreted into the circulation, which binds with high affinity to testosterone and with lower 
affinity to estradiol (E2) and modulates their bioavailability [56]. Insulin is an important regulator of 
SHBG production [57]. In addition to the liver, SHBG is also produced in other organs, including the 
brain [58], uterus [59] and testis [60]. 
The biological activity of testosterone and DHT occurs predominantly through binding to the 
AR, a member of the nuclear superfamily that function as a ligand-activated transcription factor. The 
appropriate regulation of androgen activity is necessary for a range of developmental and 
physiological processes, particularly male sexual development and maturation, as well as the 
maintenance of male reproductive organs and spermatogenesis [61]. Hypertrophy of muscle fibers is 
a process under the complex control of several myogenic pathways. Inoue and colleagues elucidated 
the role played by ARs as potential mediators of exercise-induced muscle fiber hypertrophy and 
demonstrated substantial increases in the concentration of AR in response to exercise [62,63,64]. In 
addition, satellite cells, the major source for the addition of new myonuclei into the hypertrophying 
muscle fiber, express AR and they are direct targets for testosterone action, with the increase in 
androgen-binding sites important for the regulation of pathways involved in the control of the 
satellite cell mitotic activity [65,66]. For these hypertrophic effects, for many years the anabolic 
androgenic steroids (AAS) have been used by many athletes and bodybuilders; however, it has been 
shown that supraphysiological doses can exert toxic effects on the neuron-like differentiated 
pheocromocytoma cell line PC12 [67]. 
With regards to pathways activated by hormone binding, AR associate with other effectors that 
may regulate the fate of target cells by mediating biological effects such as cell survival, profilation and 
migration. For example Filamin A (FlnA), an actin-binding protein that crosslinks actin filaments into 
the cytoplasm and participates in the anchoring ARs to the membrane, cooperates with ARs in the 
induction of non-genomic pathway, working as a scaffold. Together with its proteolytic products, FlnA 
intercepts the action of steroids at different levels and cellular compartments by hooking directly to the 
steroid receptors (e.g. AR) or effectors (e.g. GTPases) that mediate the rapid effects of steroids [68].  
Association of cSrc with AR is responsible for the rapid activation of kinase-signaling cascades 
observed in the non-genomic effects of AR, leading to enhanced kinase activity. The biological 
effects are evident through activation of the MAPK/ERK pathway, following the translocation of 
activated ERK-1/2 into the nucleus and phosphorylation of transcription factors such as Elk1, the 
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latter which regulates transcription of early genes such as c-fos that in turn acts on the expression of 
several genes controlling cell proliferation. After AR/Src activated complex formation there should 
be an association with p85; the androgen-induced ternary AR/Src/p85 complex activates downstream 
Erk-2 and Akt effectors [69]. Sometimes following cellular stimulus, Src forms a complex with 
autophosphorylated FAK, a truly multi-functional signaling protein that rapidly phosphorylates the 
p85 subunit of phosphoinositol-3-Kinase (PI-3K). PI-3K activation is accompanied by the 
downstream upregulation of the Rho small GTPases Cdc42, Rac1, RhoA and RhoB; FAK activity is 
particularly required for Rac activation. Rapid activation of these GTPases resultes in actin 
cytoskeleton reorganization affecting motility and apoptosis [70,71].  
The human androgen receptor gene is made up of 8 exons encompassing about 90 kilobases (kb) 
of DNA in the q11‒12 region of the X chromosome. Gene expression is regulated by a single 
promoter that contains two initial sites of transcription localized within a region of about 13 bases. 
Two isoforms of AR were identified: A, of 87 kDa, and B, of 110 kDa, encoding a receptor protein 
that contains a variable number of amino acids in relation to the presence of two polymorphic sites in 
the N-terminal sequence (CAGn, GGNn, SNPs) (it’s “GAG repetitions”) [72]. The AR has several 
functional domains: the transactivation domain (exon 1), the DNA binding domain (exons 2 and 3), 
the nuclear localization sequence and the hinge region (junction of exons 3 and 4), and the steroid 
binding domain (exons 4 to 8) [73]. 
The hormone-receptor complex binds activated steroid responsive elements on DNA, made up 
of a recognition core of 6 bases. Generally, these consist of two coupled cores (half-sites) separated 
by a space of variable length. The nucleotide sequence of the core is specific for subgroups of 
receptors. The androgen, glucocorticoid and progesterone receptors bind to a hexamer with a 
common sequence TGTTCT. It is important to consider that the activation of transcription occurs not 
just due to the migration of the activated hormone-receptor complex into nucleus but also for the 
action of some modulators that interact with the elements of the core sequence, in the promoter 
region, to induce basal transcription. RNA-polymerase-II and general transcription factors are 
assembled into a transcriptional complex that contains associated factors like binding protein, and 
TATA box binding proteins (TBP) [74]. The coactivators are cellular proteins that interact with the 
ligand- steroid receptor complex to raise the transactivation of target genes. 
AR is the most highly expressed receptor in breast cancer and has historically been considered 
anti-proliferative and beneficial [75]. A new class of drugs is represented by selective AR modulators 
(SARMs) that have a high specificity for AR and can control their activity and mediate the response 
to androgens. These showed an absence of virilizing side effects and this provides the possibility of 
extending androgen therapy to women [76]. 
Recently has been discovered an orphan receptor named GPRC6A, which transduces the 
non-genomic effects of testosterone; compared with the first class of receptors, the bind between 
ligand and receptor is not specific at all. GPRC6A is a pertussis toxin-sensitive member of the C 
family of GPCRs that senses calcium, amino acids and osteocalcin, all of which can activate this 
member of the G-protein family [77]. Previous studies have shown that in a cell model, removal of 
GPRC6A, rather than classic nuclear AR, abolished the intracellular signaling sensitivity to 
androgens. GPRC6A can work as a receptor for anabolic steroids and is able to coordinate the 
responses of different tissues to changes in nutrients and other factors. In this regard, the removal of 
this orphan G-protein coupled receptor involves testicular feminization in male mice, suggesting that 
GPRC6A may also modulate sex steroids and organ responses [78]. 
302 
 
AIMS Molecular Science  Volume 2, Issue 3, 294-310. 
5. Progesterone receptors 
Progestins are important steroids regulating final maturation of reproductive tissues in male and 
female vertebrates. Natural progestin in humans is progesterone, an essential regulator of normal 
human female reproductive function in the uterus, ovary, mammary gland and brain, that also plays 
an important role in non-reproductive tissues such as the cardiovascular system, bone, and the central 
nervous system, highlighting the widespread role of this hormone in normal physiology [79,80]. 
Membrane progestin receptors (mPRs), identified in 2003, are key mediators of rapid, non-genomic 
actions of progestins [81]. In addition to mPRs, there are two receptor candidates for mediating 
progestin signaling from the cell surface: nuclear progestin receptors (nPRs) and progestin receptor 
membrane components (Pgrmc). The latter are single-transmembrane proteins that include the family 
members Pgrmc 1, 2, neudesin, and neuferricin [82]. Each of these molecules is found in the brain, 
but only the first one seems to bind progesterone. In astrocytes, Pgrmc1 exerts its neuroprotective 
effetcts by increasing Brain Derived Neurotrophic Factor (BDNF) levels following activation of 
ERK signaling pathways [83]. There is data suggesting that Pgrmc1 is the same molecule as the 
sigma-2 (σ2) receptor, which is responsible for motor function and emotional response. It is possible 
that the σ2 receptor binding site could be located in Pgrmc1 and that progesterone binds both 
proteins [84].  
There are two different subtypes of σ receptors (1 and 2), with progesterone binding acting as an 
antagonist in σ-receptor-mediated modulation. The mechanisms of these actions remain still unclear. 
Since their tissue-specific expression coincides, it seems likely that their functions do as well. Thus, the 
physiological roles of receptors mediating progestin actions might be complicated and difficult to 
clarify [85,86]. For example, in addition to its function as a nuclear transcription factor, nPR modulates 
cell signaling pathways by activating c-Src and downstream MAPK pathways outside the nucleus [87]. 
The membrane progestin receptor was discovered in fish ovaries in 2002 and three related 
mPRs were subsequently identified in humans and other vertebrates, which were named mPRα, 
mPRβ and mPRγ [88]. Recently, two additional related proteins, named mPRδ and mPRε, have also 
been shown to bind progesterone [89]. These receptors have no apparent homologies with known G 
protein–coupled receptors (GPCRs) or nuclear progesterone receptors, but belong to a highly 
conserved family of proteins termed “progestin and adiponectin receptors” (PAQRs). All the PAQR 
family members have a seven-transmembrane region, but the membrane topologies of the mPRs and 
adipoQRs probably differ. Moreover, the mPRs bind small steroid molecules resulting in G-protein 
activation, whereas the adipoQRs bind the large adiponectin molecule to activate G-proteins [90]. 
Studies show that physiological concentrations of progesterone caused a decrease of intracellular cyclic 
adenosine monophospate (cAMP), which was reversed upon treatment with pertussis toxin [91]. This 
observation has been confirmed in several cell models, further supporting the coupling of mPR to G 
protein signaling [92]. 
Noteworthy are the effects of progesterone’s metabolites, allopregnanolone and its isomer 
pregnanolone, as positive allosteric modulators of GABAA receptors (an ionotropic receptor). Their 
anesthetic, anticonvulsant, sedative and anxiolytic properties are well established as well as their 
neuroprotective and neurogenic effects in neurodegenerative diseases like Alzheimer’s disease [93]. 
Another non-classical pathway by which progesterone and its metabolites elicit their effect, is 
through sigma 1 receptor binding. Since the latter is involved in neuroprotection, this may be an 
important component of progesterone’s protective properties [94]. 
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As previously mentioned, the effects of progesterone are also mediated by its nuclear receptor 
(nPR) which interacts with transcriptional coregulators, moves into nuclear aggregates (due to the 
structural constraints imposed by nuclear compartmentalization, and to the efficiency gains of 
co-location of functionally-related molecules) and regulates gene expression. More than 300 
coregulators have been described and more nPR-binding coactivators exist than are required to form 
a functional nPR activation complex. It has been hypothesized that the specific combination of 
coactivators that associate with PR in a given cell is dependent on their relative abundance, which 
varies in a tissue-specific manner [95]. 
nPR is expressed as two isoforms, PRA and PRB, which are virtually identical except that PRA 
lacks 164 amino acids that are present at the N-terminus of PRB [96]. Although the precise 
mechanisms underlying the differential activities of the two human PR isoforms is not fully 
understood, structure-function studies suggest that the AF3 domain located within the PRB upstream 
sequence region, which is absent in PRA, contributes to PRB transcriptional activity by suppressing 
the activity of an inhibitory domain (ID) contained within the sequences common to PRA and  
PRB [97]. Moreover, evidence suggests that the two receptors adopt different conformations within 
the cell allowing PRA to interact with several coregulators that are different from those that interact 
with PRB. This is supported by studies demonstrating that PRA has a higher affinity for the 
corepressor SMRT than PRB in the presence of PR antagonists, and PRA does not interact directly or 
with as high an affinity as PRB with the coactivators SRC-1 and SRC-2 upon agonist binding, 
potentially contributing to differences in the transcriptional activities of the two isoforms and further 
enhancing the complexity of this regulatory system [98,99]. 
In a cell that co-expresses both PR isoforms, there is the potential for 3 molecular species (PRB 
homodimer, PRA homodimer and PRA-PRB heterodimer) to exist at the same time and to contribute 
to the complexity of PR action. In human physiology, however, the majority of PR positive cells 
express PRA and PRB at equivalent levels, and cells that express only one PR isoform are 
uncommon. This suggests that in the human, progesterone exerts its effects in cells that co-express 
both PR isoforms, and that the PRA-PRB heterodimer is the predominant molecular species.  
In addition, the PR isoform ratio influences the capacity of PRA to regulate the activity of PRB. 
Previous studies have shown that PRA is a dominant inhibitor of the transcriptional activity of  
PRB [100]. mPR- and -activation leads the transactivation of PRB, revealing an intersection 
between classical and membrane associate signaling; the amino terminus binds to the SH3 domain of 
Src, activating Ras/Raf/ERK1/2 signaling independent of its transcriptional activity. On the other 
hand activation of the MAPK pathway results in the phosphorylation and activation of transcription 
factors such as c-Fos, c-Jun and nuclear PRs to control gene transcription.  
6. Conclusion 
The response to sex steroid hormones can be either genomic or non-genomic. The difference 
between the pathways depends upon the type of receptors that are involved. Generally, 
nuclear/cytoplasmic receptors induce a genomic response, while membrane receptors activate 
non-genomic pathways. More evidence shows that these membrane receptors exhibit characteristics of 
G-protein coupled receptors. Some examples of receptors identified that are responsible for the genomic 
response of steroids are GPR30 for estrogen, mPR for progesterone and GPRC6A for androgen.   
Sex steroid receptors associated with the non-genomic pathways are associated with the 
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modulation of intracellular calcium levels, though this seems to be through different mechanisms 
depending on the cell types. 
It is now evident that there is crosstalk between non-genomic and genomic signaling pathways, 
in which the first can regulate the latter (Figure1). For example it is known that ERK increases the 
transcriptional activity of steroid receptors directly through phosphorylation of SR and its 
coregolators. In any case, genomic and non-genomic signaling pathways can work together to 
coordinate the regulation of gene expression targets. 
 
Figure 1. Convergence between genomic and non-genomic sex steroid hormone 
receptor (HR) pathways. The molecular mechanism for HRs lacking HREs to regulate 
gene expression involve MAPK/ERKs, both of which have been shown to enhance 
transcriptional activity through direct phosphorylation of the HRs and their coregulators. 
The genomic effects of sex steroids occur through their binding to cytoplasmic steroid 
receptors. These then become active hormone-receptor complexes that can translocate to 
the nucleus and bind to sex steroid response elements in the promoters of target genes. 
Even though this is the classic model of mechanism of action, there are also indirect 
genomic effects by which sex steroid hormones act on gene expression by regulating 
other transcription factors. These pathways begin upon binding to receptors that mediate 
the membrane-initiated actions of sex steroids. In addition to classical membrane steroid 
receptors, there are novel receptors, coupled to G-proteins, that activate a protein kinase 
cascade or act at the level of secondary messengers such as PI3K/AKT/mTOR or 
PI3K/AKT/cAMP/Ca2+ or ERK-mediated pathways like PI3K/AKT/MAPK-ERK/Elk1. 
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